CHMP positive opinion recommending approval of Benlysta for adult patients with active lupus nephritis
The Pharma Data
MARCH 26, 2021
This CHMP opinion follows the recent label expansion by the US Food and Drug Administration to include LN. Make patients aware of potential risk of hypersensitivity reactions (day of, or several days after infusion, including signs/symptoms and recurrence) and provide package leaflet each time Benlysta administered.
Let's personalize your content